Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “empagliflozin” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 12
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 12 pipeline programs matching "empagliflozin" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

12 results for “empagliflozin” Back to intelligence hub

Search results

  1. Empagliflozin

    Boehringer Ingelheim

    Heart Failure

    phase 3 small molecule completed

    1 trial
  2. Empagliflozin

    Boehringer Ingelheim

    Chronic Kidney Disease

    phase 3 small molecule active

    1 trial
  3. Empagliflozin

    Boehringer Ingelheim

    Myocardial Infarction

    phase 3 small molecule completed

    1 trial
  4. Empagliflozin 10 MG

    COLLEGIUM PHARMACEUTICAL, INC

    Acute Decompensated Heart Failure

    phase 3 small molecule active

    1 trial
  5. Empagliflozin 10 MG

    Hospital Authority, Hong Kong

    Diabetic Nephropathies

    phase 3 small molecule terminated

    1 trial
  6. Empagliflozin 10 mg

    United Therapeutics Europe Ltd

    Acute Myocardial Infarction

    phase 3 small molecule completed

    1 trial
  7. Empagliflozin 20 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Metabolic Syndrome

    phase 3 small molecule active

    1 trial
  8. Bioequivalence Study of Empagliflozin

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    Not applicable (submitted trial is a BE study in healthy participants)

    phase 1 other active

    1 trial
  9. Empagliflozin 10 MG Oral Tablet [Jardiance]

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus

    phase 1 small molecule completed

    1 trial
  10. Empagliflozin 10 MG

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pre-Heart Failure

    approved small molecule active

    1 trial
  11. SGLT2 inhibitor (Empagliflozin 25 MG)

    Hospital Authority, Hong Kong

    Type2 Diabetes

    approved small molecule active

    1 trial
  12. Empagliflozin

    MEDA Pharma GmbH & Co. KG

    Non Alcoholic Fatty Liver Disease

    small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.